Senhwa Biosciences Receives NT$500 Million Commitment from GEM for AI-Driven Drug Development

April 14, 2026
Senhwa Biosciences has signed an MOU with GEM Yield Bahamas for up to NT$500 million in funding to support its AI-enabled drug discovery and global expansion.

Taipei-based Senhwa Biosciences has signed a Memorandum of Understanding with GEM Yield Bahamas, an affiliate of Global Emerging Markets, to secure up to NT$500 million in strategic funding announced in a press release. The investment will support Senhwa’s AI-enabled drug discovery programs, clinical pipeline, and international expansion.

Senhwa has been developing an AI-driven platform for oncology research, including collaborations with Y Combinator-backed company CellType. The company uses CellType’s C2S (cell-to-sentence) technology to analyze tumor microenvironments and identify potential combination therapies. AI validation has shown promising immunomodulatory effects for Senhwa’s lead candidates.

The funding from GEM is expected to accelerate Senhwa’s research in cancer immunotherapy and advance its “cold-to-hot tumor” strategy. GEM, headquartered in Luxembourg, has completed more than 590 transactions across 75 countries through its global investment vehicles.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly, AI Funding Brief or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Funding News AI Brief AI Brief (X)

More from: Life Sciences

04/14
Wavelet Medical Partners with Aegis Ventures to Advance AI Fetal Brain Monitoring
04/14
Accuity Appoints Cindy Klain as Chief Product and Strategy Officer
04/14
Harbinger Health Introduces RESOLVE for Multi-Cancer Detection
04/14
Kazia Therapeutics Licenses AI-Driven SETDB1 Drug Discovery Platform from QIMR Berghofer
04/13
Function Health Acquires Getlabs to Expand At-Home Testing Access

More from: Funding

04/14
Wavelet Medical Partners with Aegis Ventures to Advance AI Fetal Brain Monitoring
04/14
Lockheed Martin Expands Venture Fund to $1 Billion
04/14
DriveU.auto Receives Investment from Ashdod Port to Advance Autonomous Terminal Tractors
04/14
Camtek Acquires Visual Layer to Expand AI Capabilities in Semiconductor Inspection
04/14
Instacart Acquires Instaleap to Expand Global Enterprise Platform

Subscribe to AI Funding Brief

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like